Lupin Reaches Quarter-Of-A-Billion Dollar Deal Over Glumetza Antitrust Claims
Antitrust Class Action Filed In 2019; Bausch Health Settled Earlier In September
Lupin has agreed to pay $248m to settle the majority of antitrust claims against the company alleging that it caused and enabled the prolonged delayed launch of generic Glumetza, which subsequently saw a price hike of more than 800% by originator Valeant, now Bausch Health.
